Vimian Group AB Has Signed An Agreement To Acquire AllAccem Inc.

ayla-verschueren-nWKMtmbpxQs-unsplash

Vimian Group AB has signed an agreement to acquire AllAccem Inc., the provider of a veterinary dental sealant product. LGB raised preference share capital for AllAccem Inc. in 2010 and 2014. 

Founded in 2005 by Jeffery Whiteford (PhD, Chemistry), AllAccem Inc. offers a dental sealant to help prevent plaque and tartar, a leading cause of periodontal disease in dogs. The company’s main product SANOS® is sold to veterinary clinics in the United States and internationally. In addition to the dental sealant, the company also offers barrier coating products to help and aid in the management of ear infections and wounds. The proprietary formulations are produced in the company’s manufacturing facility in California. 

Vimian Group is a global animal health company covering four areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. The group is headquartered in Sweden with operating subsidiaries in the US. 

The development of AllAccem is noteworthy in that the company waited patiently for its products to be accepted by large corporate networks of veterinary clinics. For many years AllAccem’s revenues were very limited, but the company was able to control costs and become profitable. It has not required external funding since 2014. As customer adoptions increased in recent years, AllAccem achieved a growth rate of more than 50% p.a. The company had revenues of around US$ 9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. 

The acquisition terms could enable AllAccem’s preference shareholders to achieve a very attractive exit multiple. Notwithstanding the current low levels of M&A activity, this transaction indicates that exits on good valuations are possible for companies that demonstrate the following characteristics. 

  1. A proven customer value proposition evidenced by an established customer base, a high growth rate and high operating margins. 
  2. Financial and operational robustness such that the target company can remain a stand-alone entity if required. 
  3. A clear strategic fit with the buyer. Vimian Group has a strategy to expand and strengthen its veterinary dental offering.    

We hope for a general recovery in M&A volumes; but in the meantime, we are encouraging our corporate clients to enhance their attractiveness to individual strategic counterparties as AllAccem has done.